PSA Testing Cuts Deaths, Shows Value of Long-Term Screening

PSA Testing Cuts Deaths, Shows Value of Long-Term Screening
A blood test measuring the levels of PSA — a well-known marker of prostate cancer — cuts deaths from the disease by nearly 30%, the longest screening study on prostate cancer shows. The study, "Improving Prostate Cancer Screening: 22-Year Follow-up in a Randomized Trial," followed 20,000 men in Sweden for more than two decades and was featured in Maria Franlund's PhD thesis. "This research is important because it shows the long-term effects of an organized screening program in Sweden," Franlund, MD, PhD in Urology at Sahlgrenska Academy, University of Gothenburg, Sweden, and head of department at Sahlgrenska University Hospital, said in a
Subscribe or to access all post and page content.